Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details)

v3.24.3
Summary of Significant Accounting Policies (Details)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2023
Summary of Significant Accounting Policies [Line Items]                    
Comprehensive (loss) of foreign currency translation adjustment $ (67,332) $ (20,861) $ 6,460 $ 51,316 $ (15,267) $ 663 $ (81,733) $ 36,712    
Currency of subsidiaries 350     1,485     1,467 2,952    
Carrying amount                 $ 1,462,084  
Fair market value of asset                 9,063,000  
Fair market value                 0  
Exceeded of fair market values                 1,880,000  
Impaired                 3,342,084  
Reduced asset                 0  
After impairment                 9,063,000  
Loss in the amount       9,063,000       9,063,000    
Carrying amount of the IP R&D assets $ 151,138     $ 132,880     455,345 481,027    
Deferred income tax benefit             $ (2,345,025)    
CBR Pharma Subsidiary [Member]                    
Summary of Significant Accounting Policies [Line Items]                    
Carrying amount                 10,943,000  
Fair market value                 9,063,000  
Exceeded of fair market values                 1,462,084  
British pound [Member]                    
Summary of Significant Accounting Policies [Line Items]                    
Foreign currency exchange rate 1.338           1.338     1.273
Weighted average exchange rate 1.301     1.2655     1.277 2,442    
US dollar [Member]                    
Summary of Significant Accounting Policies [Line Items]                    
Foreign currency exchange rate 1           1     1
Weighted average exchange rate 1     1     1 1    
IP R&D assets [Member]                    
Summary of Significant Accounting Policies [Line Items]                    
Carrying amount                 12,405,084  
Reduced asset                 9,063,000  
Carrying amount of the IP R&D assets                  
Deferred income tax benefit               2,300,000    
One Eight Zero LP subsidiary [Member]                    
Summary of Significant Accounting Policies [Line Items]                    
Carrying amount                 $ 9,063,000  
Carrying amount of the IP R&D assets               $ 0